Volatile Non-Invasive Biomarkers of Epileptic Seizures
VIBES
2 other identifiers
observational
270
1 country
2
Brief Summary
Breath and sweat samples will be collected from people who have been admitted to hospital after a potential seizure and analysed by the team. The researchers then hope to identify a pattern of small molecules that can distinguish seizures from other events, and perhaps determine the severity of the seizure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2023
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 30, 2023
CompletedFirst Submitted
Initial submission to the registry
February 2, 2023
CompletedFirst Posted
Study publicly available on registry
February 13, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2026
ExpectedDecember 6, 2024
December 1, 2024
2.7 years
February 2, 2023
December 3, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Distinguishing epileptic from non-epileptic seizures
To distinguish epileptic from non-epileptic seizures with the detection of volatile organic compounds (VOCs) in breath and sebum samples.
3 years
Interventions
Patients will have breath samples collected by blowing into a bag, and sweat samples collected by gauze. These samples will be collected at various timepoints whilst the patients are admitted on the ward.
Eligibility Criteria
People with a diagnosis of epileptic or non-epileptic seizures
You may qualify if:
- Patients who have been admitted to either University College London's Queen's Square EEG-telemetry unit or Chalfont Centre for Epilepsy, for diagnosis of seizure events.
- Patients aged 18 years or above
You may not qualify if:
- Patients with active infection or who have taken antibiotics within 4 weeks
- Patients on immunosuppressive medications
- Patients with co-morbidities preventing breath collection
- Patients unable to provide informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University College London Hospitalslead
- Imperial College Londoncollaborator
Study Sites (2)
Chalfont Centre for Epilepsy
London, Buckinghamshire, SL9 0RJ, United Kingdom
National Hospital for Neurology and Neurosurgery
London, London, WC1N 3BG, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Matthew Walker, MB BChir FRCP
Professor
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
February 2, 2023
First Posted
February 13, 2023
Study Start
January 30, 2023
Primary Completion
October 1, 2025
Study Completion (Estimated)
November 1, 2026
Last Updated
December 6, 2024
Record last verified: 2024-12